WO2002000298A1 - Utilisation de liposomes thermosensibles - Google Patents

Utilisation de liposomes thermosensibles Download PDF

Info

Publication number
WO2002000298A1
WO2002000298A1 PCT/IL2000/000375 IL0000375W WO0200298A1 WO 2002000298 A1 WO2002000298 A1 WO 2002000298A1 IL 0000375 W IL0000375 W IL 0000375W WO 0200298 A1 WO0200298 A1 WO 0200298A1
Authority
WO
WIPO (PCT)
Prior art keywords
temperature
liposomes
tissue
liposome
imager
Prior art date
Application number
PCT/IL2000/000375
Other languages
English (en)
Inventor
Zvi Friedman
David Freundlich
Dov Maor
Yoav Medan
Original Assignee
Insightec - Image Guided Treatment, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insightec - Image Guided Treatment, Ltd. filed Critical Insightec - Image Guided Treatment, Ltd.
Priority to PCT/IL2000/000375 priority Critical patent/WO2002000298A1/fr
Priority to AU2000255610A priority patent/AU2000255610A1/en
Publication of WO2002000298A1 publication Critical patent/WO2002000298A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01K—MEASURING TEMPERATURE; MEASURING QUANTITY OF HEAT; THERMALLY-SENSITIVE ELEMENTS NOT OTHERWISE PROVIDED FOR
    • G01K11/00—Measuring temperature based upon physical or chemical changes not covered by groups G01K3/00, G01K5/00, G01K7/00 or G01K9/00
    • G01K11/20—Measuring temperature based upon physical or chemical changes not covered by groups G01K3/00, G01K5/00, G01K7/00 or G01K9/00 using thermoluminescent materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/01—Measuring temperature of body parts ; Diagnostic temperature sensing, e.g. for malignant or inflamed tissue
    • A61B5/015—By temperature mapping of body part
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N7/00—Ultrasound therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy

Definitions

  • the present invention relates to the field of therapeutic ultrasound, and especially to treatment and/or monitoring of treatment using temperature-sensitive hposomes.
  • hposomes Lipid coated gas-filled micro-bubbles
  • An aspect of some exemplary embodiments of the invention relates to monitoring a temperature inside a patient, using temperature-sensitive liposomes.
  • a mixture of a plurality of different sets of liposomes is used, each set of liposome having a phase transition at a different temperature.
  • different liposomes will collapse at different temperatures.
  • the liposomes that collapse at different temperatures have different sizes.
  • others structural distinctions, such as contents or wall thickness differentiate between liposomes that collapse at different temperatures.
  • the temperature at a location heated by ultrasound is inversely related to the amplitude of the reflection from the liposomes, since, as the temperature rises, more liposomes are burst.
  • the mixture of liposomes may be selected to provide a discrete temperate scale or a quasi-continuous scale.
  • a discrete scale the liposome phase transition temperatures are clustered in groups at the temperature scale points of interest.
  • the phase transition temperatures are more evenly distributed in the temperature range of interest.
  • the temperature scale is continuous in some parts and discrete in others.
  • the liposomes are selected to give a temperature resolution of about 1°.
  • ultrasonic waves are used both for imaging the liposomes and, with an increased intensity, for collapsing them.
  • light is used to detect the liposomes, for example, by detecting a Doppler shift in light reflected from ultrasound-excited liposomes.
  • ultrasonic heating is preferred in some embodiments, other heating methods, such as RF, laser and hot-water bath may be used.
  • a volume to be treated using thermal therapy is surrounded by a volume not to be treated. In an exemplary embodiment of the invention, this surrounding volume is provided with liposomes, so that inadvertent heating of not-to-be-treated volume is signaled by a creation of a non-reflecting volume. Heating in this surrounding volume may be detected automatically or manually.
  • a heat-dosage measurement (integrated temperature) can be obtained, alternatively or additionally to a relatively instant temperature measurement.
  • an aspect of some exemplary embodiments of the invention relates to controlling the release of chemicals in the body, especially pharmaceuticals, by selectively heating temperature sensitive liposomes.
  • the released chemical is one that assists the activity of a second chemical, for example by modifying reaction conditions, such as pH.
  • the released chemical assists in the absorption of a pharmaceutical.
  • a release of Mannitol opens a blood-brain barrier for a second chemical.
  • the second chemical is also provided using temperature sensitive liposomes, although other local and/or systemic delivery systems may be used instead.
  • the liposomes are designed to collapse and release an enclosed chemical, at a temperature at which the enclosed chemical has a desired effect.
  • An aspect of some exemplary embodiments of the invention relates to controlling the provision of liposomes and/or a therapeutic chemical to a volume being thermally treated, using the liposomes themselves.
  • a volume is heated, blood supply to that volume increases.
  • temperature-triggered liposomes are provided enclosing a vasodilator.
  • the liposomes collapse, freeing a chemical which will enhance the inflow of blood over and above that provided by heating alone, and encourage the inflow of blood carried materials, such as additional liposomes (of a same or different type) or of a blood carried therapeutic.
  • the vasodilator may have a local effect and/or a more regional effect, depending on the particular vasodilator chosen.
  • the liposomes may enclose a vasostrictor chemical, to block further inflow of blood (and export of heat and/or therapeutics) from the heated volume.
  • Both types of vascular control chemicals may be provided, for example sequentially, or to be triggered at different temperatures, with, for example, the vasodilator being triggered at a first, lower temperature and the vasostrictor being provided at a second, higher, temperature.
  • An aspect of some exemplary embodiments of the invention relates to providing two- part pharmaceuticals at a locality, by selectively heating the locality, for example when both pharmaceuticals are locally present.
  • the two pharmaceuticals work together.
  • a two step treatment is provided, in which a second step is applied in response to an effect of the first step.
  • the effects of the first step are monitored using ultrasonic imaging.
  • An aspect of some exemplary embodiments of the invention relates to a method of removing a toxic drug from the body, in which temperature-sensitive liposomes containing the pharmaceutical are collapsed at a location in the body at which they do less damage, by heating that location.
  • the tissue at the location may be less sensitive to damage at the location or an antidote to the chemical may be provided thereat.
  • An aspect of some exemplary embodiments of the invention relates to a method of marking a volume to be treated in which liposomes containing a contrast material are selectively collapsed at desired locations.
  • a marking of a volume to be treated and/or fiduciary marks or other markings may be generated inside the body, substantially non- invasively.
  • the markings are used to guide the procedure.
  • various effects such as marking of zones, can be achieved.
  • the contrast material is toxic, for example Gd+3, so localized delivery enables reducing the total amount of toxic material delivered and/or restricting its spatial distribution.
  • An aspect of some exemplary embodiments of the invention relates to providing a toxic material at limited location, by collapsing liposomes encapsulating the material only at the locality or a vascular bed thereof, using localized heating.
  • the toxic material is urokinease for clot dissolving, where its release by heating damages a blood vessel significantly less than would its release by cavitation.
  • Other exemplary toxic materials are contrast materials, such as Gd+3.
  • An aspect of some exemplary embodiments of the invention relates to a method of indicating temperatures for non-ultrasonic type imaging.
  • temperature-sensitive liposomes which act as a contrast material, for example, as a result of their structure or contents, are provided in the body. As a result of the temperature, the liposomes fail and collapse and their contents dilute, thereby reducing or eliminating the contrast.
  • Exemplary imaging methods for which this method can work include, US, NM, CT, MRI and/or combinations.
  • An aspect of some exemplary embodiments of the invention relates to a method of calibration of temperature sensitive imaging techniques. Many such imaging techniques provide images whose pixel values are affected by the tissue constituents as well as by the actual temperature.
  • temperature-sensitive MRI sequences are affected to a great degree by the ratio of fat to muscle tissue in the imaged tissue, since different tissue types have different temperature dependent image characteristics.
  • temperature sensitive liposomes are used to determine the true temperature inside the body. This true temperature is used to calibrate an imaging sequence, for example by determining a fat/muscle ratio of that volume and/or for determining a function of phase change as a function of temperature.
  • An aspect of some exemplary embodiments of the invention relates to a method of targeted therapy.
  • a temperature-sensitive liposome having an affinity for a certain structure for example by being encapsulated or ligated with a suitable anti-body, is provided in the body. Once it is determined to be located at the locality, the liposome is collapsed using heat, for example ultrasound or RF, so that a therapeutic contents of the liposome is locally released.
  • apparatus for temperature-monitored heat treatment monitoring comprising: a radiant heat source adapted for heating of internal body tissue at a location; an imager suitable for providing an image that differentiates between whole and collapsed liposomes, viewing said heated tissue at said location; and a controller that analyses a view of said tissue acquired by said viewer and generates a temperature indicating map of the heated tissue, based on a known temperature-varying collapse characteristic of said liposomes.
  • said radiant heat source comprises an ultrasound source.
  • said radiant heat source is adapted for transcutaneous heating.
  • said imager is a one dimensional imager.
  • said imager is a two dimensional imager.
  • said imager is a three dimensional imager.
  • said imager is a point imager that generates a scalar image of a single point volume.
  • said imager comprises an ultrasound imager.
  • said imager detects waves that are related to transmitted waves by nonlinear response of said liposomes.
  • said imager comprises a separate ultrasound source from said radiant heat source.
  • said imager uses said radiant heat source as an ultrasound source for imaging.
  • said imager comprises a light source having a wavelength reflected by said liposomes and a Doppler shift optical detector to detect Doppler shifted reflections from said liposomes.
  • said radiant heat source comprises an RF source.
  • said temperature indicating map include absolute temperature indications.
  • the apparatus comprises a display for displaying said map.
  • the apparatus comprises a heating monitor that determines that a required temperature is reached in a target portion of said location.
  • the apparatus comprises a danger monitor that determines that a danger temperature is not exceeded in a non-target portion of said location.
  • the apparatus comprises a dosage monitor that determines that an integrated temperature dosage is not exceeded in a non-target portion of said location.
  • said controller modifies an activity of said radiant heat source responsive to said map.
  • said activity comprises a spatial localization of the heating.
  • said activity comprises a heating intensity.
  • the apparatus comprises a pharmaceutical pump that provides at least one pharmaceutical to a body containing said tissue such that at least some of said pharmaceutical is carried to said location, wherein said controller modifies an activity of said pump responsive to said map.
  • said activity comprises a flow rate.
  • said liposomes comprises a plurality of liposome sets, each set having a distinct and different collapsing temperature, which different sets are distinguished by said controller.
  • at least one of said sets has a collapsing temperature of about 38°.
  • at least one of said sets has a collapsing temperature of about 42°.
  • at least one of said sets has a collapsing temperature of about 44°.
  • said plurality of sets comprises at least three sets.
  • said plurality of sets comprises at least four sets.
  • said liposomes comprises at least one set of liposomes having a continuous distribution of temperature collapse characteristic over a range of temperatures.
  • a liposome comprising: a temperature sensitive liposome body; and an encapsulated indirect activity chemical, which chemical comprises at least one of a tissue barrier control agent, a toxic non-optical contrast agent, a clot dissolution agent, a vasostriction control agent or a component of a binary chemical treatment.
  • the liposome comprises a chemical therapy agent, whose activity is enhanced by said indirect activity agent.
  • a method for analyzing images to calibrate a temperature sensitive imaging method comprising: receiving at least one liposome-showing image of a temperature-sensitive liposome containing tissue; receiving at least one temperature sensitive image of the tissue, using a temperature sensitive imaging method; and analyzing said images to determine a temperature sensitive behavior of said tissue under said temperature sensitive imaging method.
  • said liposome based image comprises an ultrasound image.
  • said liposome based image comprises an MRI image.
  • said temperature sensitive image is an MRI image.
  • said at least one temperature sensitive image comprises at least two temperature sensitive images taken at different temperature conditions.
  • said at least one temperature sensitive image comprises at least three temperature sensitive images taken at different temperature conditions.
  • said at least one liposome image comprises at least two liposome images taken at different temperature conditions.
  • said at least one liposome image comprises at least three liposome images taken at different temperature conditions.
  • FIG. 1A-1C illustrate a body part to be treated and as viewed prior to and during therapy, in accordance with an exemplary embodiment of the invention
  • FIG. 2 is a schematic block diagram illustration of an ultrasonic imaging and therapy device, in accordance with an exemplary embodiment of the invention
  • Fig. 3 is a graph showing the dependence of a reflection intensity on the temperature, in accordance with some embodiments of the invention.
  • Figs. 4A and 4B illustrate a temperature sensitive image acquired in an ultrasound modality and in an MRI modality, respectively, in accordance with an exemplary embodiment of the invention
  • Fig. 5 is a flowchart of a method of temperature calibration, in accordance with an exemplary embodiment of the invention.
  • Fig. 6 is a schematic illustration of a therapy for brain lesions, in accordance with an exemplary embodiment of the invention.
  • Fig. 7 is a flowchart of a method of dual-chemical treatment, in accordance with an exemplary embodiment of the invention.
  • Fig. 8 illustrates a body tissue marked with a contrast agent, in accordance with an exemplary embodiment of the invention
  • Fig. 9 illustrates providing urokinease to dissolve a clot, in accordance with an exemplary embodiment of the invention.
  • Fig. 10 illustrates a method of blood flow control utilizing liposomes, in accordance with an exemplary embodiment of the invention.
  • Figs. 1A-1C illustrate a body part 100 to be treated and as viewed prior to and during therapy, in accordance with an exemplary embodiment of the invention.
  • body part 100 includes a tumor 102 adjacent to healthy tissue 104.
  • Fig. 1A shows body part 100 as it would be viewed, for example using ultrasound imaging, without any particular contrast agent.
  • Body part 100 may be any part of the body, but it may especially be tissues where lesions and small sensitive structures are adjacent, for example the eyes and the brain.
  • Fig. IB shows the effect of injecting temperature sensitive liposomes so that they reach body part 100.
  • the liposomes may be locally or systemically provided.
  • tumor 102 will be darker (if gray scale is inversely related to the intensity of reflection or lighter, for some imaging techniques and/or other parameter settings, for example reversing the gain) than other tissue, as it contains more blood vessels and/or liposomes are more likely to lodge in tumor tissue than in healthy tissue, as the blood vessels of tumor tissue are typically somewhat more permeable.
  • the liposomes are gas enclosing liposomes.
  • Exemplary gasses include air, CO2, and perflourocarbons.
  • at least some of the enclosed volume may include other chemicals, which may be, for example, gaseous, liquid or solid.
  • Fig. 1C shows body part 100 during thermal therapy, provided, for example, using ultrasound.
  • other types of heating such as RF, may be used.
  • RF radio frequency
  • a volume 108 that has already been heat-treated is lighter (fewer reflections), as the reflection from tissue is weaker than the reflection from liposomes.
  • a mixture of different sets of liposomes is provided, each set collapsing at a different temperature.
  • the temperature in the tissue is inversely related to the intensity of ultrasound reflection.
  • a volume 106 inside the healthy tissue 104 may also be affected by the heat treatment, for example being a secondary ultrasound focal point or a microwave node location. This heating is undesirable, as it may damage healthy tissue 104.
  • the presence of this heating is detected by viewing volume 106, with viewing parameters such that the image is dependent on the collapse state of the liposomes, thereby indicating the local temperature and/or duration of the temperature application.
  • a liposome is selected to have similar dosage/temperature heat-damage characteristics as a human cell of interest, for example, so that it collapses when the tissue is expected to be damaged, or shortly before.
  • the heat-treatment can be modified, for example to move the node, or pause the heating.
  • liposomes including a local vessel dilator chemical are provided at the periphery of the heat-treated volume, to assist in heat removal from that peripheral volume.
  • the location of the heat source can be changed, thereby spreading inadvertently heated volume 106 over a larger part of healthy tissue 104 and reducing the damage.
  • volume 108 by persisting in its lower reflection intensity, also provides an assurance that all of tumor 102 has been treated.
  • new liposomes may enter the tissue and provide a reflection.
  • such liposomes are intentionally provided to "regenerate" the liposomes in volume 106, so that the hot-spot detection mechanism can be used again.
  • the rate of regeneration can be used as an indication of heat dosage and/or thermal flow.
  • liposomes including vessel constricting (or dilating) chemicals are provided to reduce (or increase) the liposome replacement rate and/or cooling rate.
  • Fig. 2 is a schematic block diagram illustration of an ultrasonic imaging and therapy device 120, in accordance with an exemplary embodiment of the invention.
  • device 120 includes an ultrasonic transmitter 124 for transmitting waves to body part 100, and an ultrasonic receiver 128 for receiving the reflection of the waves from the tissue and the liposomes.
  • the liposomes are imaged separately from the rest of the tissue, for example by receiver 128 being tuned especially to detect non-linear interactions of the transmitted ultrasonic waves and the liposomes.
  • Transmitter 124 may also be used for providing ultrasonic energy to heat body part 100. Alternatively or additionally, a separate ultrasound transmitter (not shown) for heating is provided.
  • system 120 monitors and/or controls heating effects of cavitation, however, typically, regular heating effects are desired.
  • a heater 126 for example an RF heating element, is used to provide the heating, while the ultrasound elements are used to provide feedback on the therapy.
  • other imaging methods that detect the presence or absence of liposomes may be used, for example MRI and X-RAY CT may be used.
  • the liposomes may contain a contrast material that is imaged by the imaging method and is concentrated enough only so long as the liposome does not collapse from heating. Alternatively or additionally, the liposome itself is imaged.
  • transmitter 124 and/or receiver 128 include optical transmission and receiving elements.
  • a liposome When a liposome is irradiated by ultrasound waves from transmitter 124 or heater 126, light reflected from the liposome is Doppler shifted by the induced vibration of the liposome.
  • 250 nm diameter liposomes (with or without gas filling) are illuminated using 800 nm wavelength infra-red light, for example from a laser source.
  • Other liposome geometries may be selected for other light sources, or vice versa, for example first selecting a light source and then selecting a liposome size to match the light source.
  • multiple liposome diameters are provided, so that different liposomes reflect different wavelengths of light.
  • different temperature sensitivities are associated with different diameters, so that a tissue temperature can be estimated by a relative signal intensity at different illumination wavelengths.
  • the liposomes include an optical contrast material, such as ICG, which changes its optical properties when released from a liposome (which may contain one solvent environment) into the blood stream (which generally comprises a second solvent environment).
  • ICG optical contrast material
  • a shift of an absorption band of several tens of nm is expected when ICG is released from the liposome and comes into contact with albumin.
  • a second shift of the absorption spectra is detected when the material is taken up by the cells.
  • a third shift of the absorption spectra is detected when the ICG is in the presence of a material released from other liposomes, such as anti-cancer drugs.
  • optical contrast materials may be provided, for example materials whose absorption or reflection spectra is changed by a change in pH (between inside and outside the liposome).
  • a signal processor 130 is optionally provided for analyzing the reflections detected by receiver 128.
  • a controller 122 optionally controls device 120, for example synchronizing the transmission and reception of signals.
  • a display 132 is provided so that a user can view the effect of the therapy (at least on the liposomes) in real-time.
  • a user enters the liposome parameters, for example one or more of type(s) of liposomes used, amounts and time(s) of injection.
  • the display presents either a detected temperature or a liposome degradation display showing the degradation rate and/or the degradation as a function of time.
  • a watchdog program or hardware 134 is provided, which can generate an alert and/or shut-down the heating if a portion of healthy tissue 104 is inadvertently heated above a described temperature.
  • a user interface 136 is optionally provided for controlling device 120.
  • a graphical interface is provided and used to delineate volumes to be heated and/or not to be heated on a display such as that of Fig. IB.
  • device 120 at least insofar as its hardware, is substantially a standard heat-treatment and/or imaging system.
  • a stored program memory 138 which can be used by controller 122, is optionally provided to provide required functions so that device 120 can operate as described herein.
  • an ultrasonic image guided heating therapy device may be reprogrammed to be used as device 120, especially with regard to determining temperature based on liposome collapse.
  • a suitable windowing is used, to allow the different densities of liposomes to be viewed as temperatures.
  • a displayed color may vary as a function of the temperature (inverse intensity of reflection from liposomes).
  • non-linear effects such as can be viewed using second harmonic imaging are used to selectively image (and thus display) the liposomes.
  • the treatment is manually directed.
  • the treatment is automatically directed, for example responsive to echoes from the tumor that indicate that not all the liposomes have collapsed, e.g., that a required temperature has not been reached, a variety of responses may be performed, for example, a heating may be increased, decreased, started or stopped and/or provision of a pharmaceutical from an associated pharmaceutical pump may be increased, decreased and/or the pharmaceutical changed.
  • such automatic directing utilizes the ability to image the location of the heat source.
  • the treatment is preferably transcutaneous, in some embodiments, the treatment is applied during minimally invasive (e.g., using a heater and/or imager on an endoscope or catheter) or open surgery.
  • Receiver 128 is preferably adapted to generate a 2D or 3D image, however, in some embodiments of the invention, the receiver only generates a one dimensional image. In some embodiments of the invention receiver 128 generates a scalar value, for example for indicating temperature at a preset or controllable position relative to the receiver.
  • Fig. 3 is a graph 150 showing the dependence of a reflection intensity on the temperature, in accordance with exemplary embodiments of the invention.
  • Line 152 refers to a situation in which a substantially uniform distribution of temperature sensitivities is used. Thus, as the temperature increases, more liposomes collapse and the reflection intensity goes down.
  • Line 154 refers to a situation in which a non-uniform distribution is used, for example including only liposomes for specific temperatures of interest. Thus, a step-wise response is expected. Generally, the sharpness of the steps depends on the degree of control available during liposome preparation. In the particular example shown a plurality of temperatures are used.
  • thresholds are of interest so fewer sets of liposomes will be provided, increasing the size of step when the threshold is passed and, possibly, increasing the detectability of the step.
  • some non-temperature sensitive liposomes are also provided (or liposomes that are sensitive at significantly higher temperatures), so that even at high temperatures, at least a reference signal from some liposomes can be detected.
  • the temperature monitoring method may be used to monitor heat therapy, it may also be used for temperature measurement for other uses, for example studying heat propagation through the body and for studying blood flow to ischemic and/or damaged tissue.
  • temperature-sensitive liposomes are used to calibrate a different temperature-sensitive imaging method.
  • Figs. 4A and 4B illustrate a temperature sensitive image of a body part 160 acquired in an ultrasound modality and in an MRI modality, respectively, in accordance with an exemplary embodiment of the invention.
  • Body part 160 comprises, for example a bone 162, a muscle tissue 164 and a fatty tissue 166.
  • tissue types are not binary and a mixture of different tissue types exists in each section of the body.
  • Fig. 4A illustrates an ultrasound image, in which bone is white (as all the waves are reflected from its surface) and both fat and tissue, that incorporate temperature sensitive-liposomes, have substantially a same reflection intensity. This picture is not expected to change as the temperature increases, except that the intensity of reflection from both of tissues 166 and 164 will change by a same amount.
  • the change in intensity as a function of temperature, in a particular tissue is optionally significantly less dependent on the tissue type than the changes caused by passing a critical temperature threshold at which liposomes collapse, at which temperature threshold the ratios are optionally determined and the system calibrated.
  • a critical temperature threshold at which liposomes collapse at which temperature threshold the ratios are optionally determined and the system calibrated.
  • non-linear interaction of the liposomes with the ultrasonic waves are used to detect them.
  • Fig. 4B is an image acquired using a temperature sensitive MRI sequence. Such sequences usually detect temperature differences by a phase shift in a detected RF signal, caused by the temperature. However, this phase shift is also affected by the type of tissue imaged. Thus, the picture of Fig. 4B will change, with respect to relative density of tissues 164 and 166, as the temperature changes. Exemplary sequences of temperature-sensitive MRI imaging are described in US patents 5,711,300 and 5,307,812, the disclosures of which are incorporated herein by reference.
  • Fig. 5 is a flowchart 170 of a method of temperature calibration, in accordance with an exemplary embodiment of the invention.
  • An image using MRI (172) and an image using ultrasound (174) are optionally acquired.
  • the order is not critical, however, in some cases, it may be useful to acquire the MRI image either with the liposomes or without, prompting a particular acquisition order.
  • an MRI image is used to detect the degree of presence of liposomes.
  • Exemplary images are shown in Figs. 4A and 4B, above. From these two images, it is possible to determine the approximate tissue dependent characteristics (e.g., of phase-temperature relationship).
  • the image acquisitions are repeated at a second or even a third temperature (176).
  • the effects of changes in temperature can be determined and compared.
  • the temperature changes are expected not to depend directly on tissue type, only on liposome concentration, while in the MRI image they are expected to also depend on the tissue type.
  • the result can be calibration parameters for the particular body part imaged (178).
  • a determination of fat/muscle ratio for the tissue, or other tissue characteristics can be made based on the temperature dependencies. It should be noted that a single image can provide a temperature dependency behavior of the tissue, in some embodiments of the invention, for example, if a same tissue is heated in an irregular pattern. Each different temperature location can be utilized as a different image for purposes of calibration.
  • Fig. 6 is a schematic illustration of a therapy for brain lesions, in accordance with an exemplary embodiment of the invention.
  • a lesion 204 is generally near one or more blood vessels 202.
  • a plurality of therapy- vector carrying liposomes 210 can be provided in vessel 202, however, due to a blood brain barrier, symbolized here by a plurality of pores 208, the liposomes and/or the vector itself cannot enter lesion 204.
  • a plurality of enabling liposomes 206 are also provided.
  • Enabling liposomes 206 encapsulate a material, for example Mannitol or Bradykinin analogs, that causes the blood-brain barrier to open. Same or other chemicals may be used to effect opening of other endothelial tissues and/or blood vessels in other parts of the body.
  • a material for example Mannitol or Bradykinin analogs, that causes the blood-brain barrier to open. Same or other chemicals may be used to effect opening of other endothelial tissues and/or blood vessels in other parts of the body.
  • liposomes 206 are temperature sensitive liposomes that are collapsed by heating the vicinity of lesion 204. It is noted that regular heating, such as using RF or ultrasound may be more desirable than cavitation level ultrasound beams and/or can be better controlled, as they require lower power levels. Additionally, simpler equipment, for example imaging-power-level equipment can be used.
  • therapy vector is optionally provided using liposomes, alternatively, other provision methods, such as local injection or systemic injection may be used instead.
  • the enabling composition and the therapy vector may be encapsulated in a single liposome.
  • the pharmaceutical(s) used may interact with the temperature, in that they have an optimal effect at a similar temperature to that at which the liposomes collapse. Possibly, both pharmaceuticals are released by heating temperature sensitive liposomes, each one sensitive to a different temperature. Thus, it can be assured that both pharmaceuticals will be released in a desired order or simultaneously (if same type of liposomes).
  • the local concentration of a phannaceutical may be controlled over time by providing a same pharmaceuticals in a variety of temperature-sensitivity levels and selectively collapsing liposomes to achieve a desired effect.
  • a concentration of the pharmaceutical is determined by mixing a contrast material in with the liposomes and differentiating between the signals from the contrast material (which represents the free and encapsulated pharmaceutical and the reflections from the liposomes (which represents only the encapsulated pharmaceutical).
  • Fig. 7 is a flowchart 220 of a method of dual-chemical treatment, in accordance with an exemplary embodiment of the invention.
  • Both a first and a second drug are provided (222, 226) and released (228, 224) optionally using temperature sensitive liposomes.
  • the drugs are provided together or in a certain order.
  • the second drug may also be provided only after the first drug is released, possibly after it is removed from the target volume.
  • one drug may be a systemic or a local antidote for the other drug.
  • the drags may be part of a two step treatment. As described above, it may be desirable for the two drugs to be released simultaneously, for example being encapsulated in a same type liposome.
  • This may be useful, for example, for two-part pharmaceuticals or for treatments in which there is a synergetic interaction between the drugs.
  • simultaneous or consecutive release is useful when one drug enables the other drug to operate, for example by opening tissue or cellular barriers (e.g., Mannitol then a Galanin antagonist for Alzheimer's disease) or by modifying pH or other chemical environment variables. Consecutive release may be achieved, for example, by setting different temperature thresholds or different heat dosages for the collapse of different liposomes.
  • an optional step of applying a treatment may be performed.
  • a treatment such as heating
  • an assessment of the effect of the total process may be assessed.
  • one drug is released at a first location and a second drug at a second location.
  • temperature-sensitive liposomes are intentionally collapsed at locations where their contents will not cause damage, for example where they will be diluted or where an antidote is present.
  • a toxic drug can be safely removed from the body, typically after a desired amount was already liberated at a treatment zone.
  • the liposomes flow through the volume, for example as a bolus, and the application of heating is optionally timed to the appearance of the bolus.
  • the liposomes accumulate in the volume, for example as a result of the lesion, as a result of accumulating all over the body, as a result of attraction to certain tissue types and/or as a result of local injection and/or local control of the blood supply.
  • the application of heat is optionally started after there is a feedback (e.g., ultrasound reflection) that the liposomes are properly placed.
  • the liposome includes, in its coating an agent with an affinity for certain tissue, thus, aiding in the accumulation of liposomes at desired locations.
  • Fig. 8 illustrates a body tissue 300 marked with a contrast agent, in accordance with an exemplary embodiment of the invention.
  • a persisting contrast agent is provided. Once the contrast agent is released (e.g., during heat therapy or during a dedicated marking session), it persists in the locality where it was released, for a significant period of time. This contrast agent is optionally used during therapy of the locality, for example to aid in identifying a lesion and/or to mark sensitive tissues.
  • the type of contrast agent is adapted for the type of therapy and the type of guidance used, for example, adhesive liposomes for ultrasound guided therapy and endoscopes, visible, invisible and florescent dyes for open surgery and optical endoscopes, MRI-contrast agents for MRI and radio-opaque or radioactive materials for X-ray guided and nuclear imaging guided therapies.
  • an MRI imaging sequence is used to guide an ultrasound heating-beam so that a lesion 306 is marked (by heating liposomes to release a dye). Thereafter, during open surgery, for example to remove remainders of a tumor, the boundaries of the lesion can be easily seen.
  • a marking 310 is used to warn about the presence of a nearby sensitive tissue 308.
  • the marked volumes can serve as fiduciary marks which guide the navigation and/or other aspect of the procedure.
  • a plurality of marks 304 can serve to guide a catheter to tumor 306, in a vascular tree 302. Such guidance is especially important in tissues that change shape periodically or as a result of the therapy, such as the lungs or the brain.
  • a temperature sensitive liposome may also comprise a second liposome, either temperature-sensitive or not, for example an adhesive liposome which can serve as an ultrasound contrast agent.
  • Encapsulation and then local release of a contrast agent is also useful if the agent is toxic, for example Gd+3, thus allowing a smaller and/or temporally controlled amount of toxic material to be released in contact with specific body tissues.
  • FIG. 9 illustrates providing urokinase to dissolve a clot 324, in accordance with an exemplary embodiment of the invention.
  • a clot 324 (complete as shown, or partial) is formed in a vessel 320.
  • a plurality of liposomes 322 encapsulating a clot dissolution material, such as urokinase are provided near clot 324, for example using systemic or local injection or using an endoscope.
  • a heater 328 for example using focused ultrasound heats a volume 326 near clot 324, such that the heated liposomes collapse and release a clot dissolution material.
  • volume 326 is heated, the released material does not damage other portions of blood vessel 320.
  • the heat intensity is much lower, so the heating itself does not cause considerable damage. It is noted that ultrasound heating in general is less damaging than ultrasound cavitation effects.
  • the heater may also be a non-focused heater, for example a hot bottle. Alternatively other types of external focus or unfocused heaters may be used. Further, the heater may be on a catheter or needle that provides the liposomes.
  • clot 324 is not a complete occlusion, blood will flow by it. However, if such flow is low enough and/or the heating is intense enough, the clot dissolution material will be locally released to do its work of dissolving the clot, and when washed away will be replenished from the upstream portions of vessel 320 or from the catheter. In some embodiments, no catheter is used and the liposomes are provided systemically or locally, for example using an injection.
  • Fig. 10 illustrates a method of blood flow control utilizing liposomes, in accordance with an exemplary embodiment of the invention.
  • a lesion 332 and a sensitive tissue 334 in a body part 300 are both affected by a heater 344, tissue 332 being affected in a desirable manner and tissue 334 in an undesirable manner.
  • a first type of possibly desirable effect is preferentially providing a chemical or liposomes to tissue 332.
  • a vessel 336 provides blood with liposomes 340 therein to tissue 332. If the liposomes encapsulate a vasodilator, such as lactic acid, acetyl-choline or Bradykinin, when tissue 332 is heated, vessel 336 will provide more blood to tissue 332, bringing the desired chemical and/or liposomes. Thus, more of the chemical will arrive at tissue 332 than at tissue 334. It is noted that also plain heating increases vascular flow, however, by providing chemical signaling molecules, an even further increased flow can be achieved.
  • the vasodilator type may be local (nearby vessels), semi-local or even body wide, in some embodiments.
  • the released materials may be short term, medium term or long term onset and/or duration vascular control substances. It is noted that some capillaries open only occasionally. Such a vasodilator may be used to force them to open and enhance the penetration of liposomes and therapeutic materials.
  • liposomes 340 may include a vessel constricting chemical, for example to compensate for the increased flow brought about by the heat and/or to reduce the outflow of heat and locally (or systemically) released chemicals.
  • a vasodilator may be used to protect sensitive tissue 334, by increasing blood supply to tissue 334, thereby increasing heat losses.
  • liposomes may be supplied to different tissues.
  • a mixture of liposome sets may be supplied, for example to promote a range effect e.g., restricted blood flow up to one temperature threshold and increased flow above it.
  • the different types of liposomes, therapeutic chemicals and application of heating may be timed to have a desired effect, for example:

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Thermotherapy And Cooling Therapy Devices (AREA)
  • Surgical Instruments (AREA)

Abstract

L'invention porte sur un appareil de régulation de traitements thermiques à suivi des températures comportant: une source de chaleur radiative conçu pour réchauffer un emplacement de tissus internes du corps, un dispositif de visualisation fournissant une image différenciant les liposomes entiers des liposomes affaissés et figurant les tissus chauffés, et un contrôleur analysant l'image desdits tissus chauffés et en produisant une carte thermique basée sur les caractéristiques connues de variation de l'affaissement desdits liposomes en fonction de la température.
PCT/IL2000/000375 2000-06-28 2000-06-28 Utilisation de liposomes thermosensibles WO2002000298A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/IL2000/000375 WO2002000298A1 (fr) 2000-06-28 2000-06-28 Utilisation de liposomes thermosensibles
AU2000255610A AU2000255610A1 (en) 2000-06-28 2000-06-28 Use of temperature sensitive liposomes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IL2000/000375 WO2002000298A1 (fr) 2000-06-28 2000-06-28 Utilisation de liposomes thermosensibles

Publications (1)

Publication Number Publication Date
WO2002000298A1 true WO2002000298A1 (fr) 2002-01-03

Family

ID=11042984

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2000/000375 WO2002000298A1 (fr) 2000-06-28 2000-06-28 Utilisation de liposomes thermosensibles

Country Status (2)

Country Link
AU (1) AU2000255610A1 (fr)
WO (1) WO2002000298A1 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6542767B1 (en) * 1999-11-09 2003-04-01 Biotex, Inc. Method and system for controlling heat delivery to a target
WO2010026357A1 (fr) * 2008-09-08 2010-03-11 Institut Curie Procede et dispositif de marquage d'un milieu, et marqueur utilisable dans un tel procede.
US9211157B2 (en) 2009-08-13 2015-12-15 Monteris Medical Corporation Probe driver
US9333038B2 (en) 2000-06-15 2016-05-10 Monteris Medical Corporation Hyperthermia treatment and probe therefore
US9339336B2 (en) 2003-11-07 2016-05-17 Visualase, Inc. Cooled laser fiber and method for improved thermal therapy
US9403029B2 (en) 2007-07-18 2016-08-02 Visualase, Inc. Systems and methods for thermal therapy
US9433383B2 (en) 2014-03-18 2016-09-06 Monteris Medical Corporation Image-guided therapy of a tissue
US9504484B2 (en) 2014-03-18 2016-11-29 Monteris Medical Corporation Image-guided therapy of a tissue
US10327830B2 (en) 2015-04-01 2019-06-25 Monteris Medical Corporation Cryotherapy, thermal therapy, temperature modulation therapy, and probe apparatus therefor
US10675113B2 (en) 2014-03-18 2020-06-09 Monteris Medical Corporation Automated therapy of a three-dimensional tissue region
US11172821B2 (en) 2016-04-28 2021-11-16 Medtronic Navigation, Inc. Navigation and local thermometry

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5190766A (en) * 1990-04-16 1993-03-02 Ken Ishihara Method of controlling drug release by resonant sound wave
US5307812A (en) 1993-03-26 1994-05-03 General Electric Company Heat surgery system monitored by real-time magnetic resonance profiling
EP0800822A2 (fr) * 1996-04-11 1997-10-15 Mitsubishi Chemical Corporation Méthode de préparation de vésicules closes par réhydratation de vésicules déshydratées
US5711300A (en) 1995-08-16 1998-01-27 General Electric Company Real time in vivo measurement of temperature changes with NMR imaging
US5720976A (en) * 1996-01-30 1998-02-24 Korea Advanced Institute Of Science And Technology Thermosensitive liposome and process for preparing the same
EP0834309A2 (fr) * 1996-09-27 1998-04-08 Artur Herzog Dr. Mesmer Utilisation d'une solution de liposomes pour augmenter l'activité et/ou diminuer la toxicité de médicaments
US5810888A (en) * 1997-06-26 1998-09-22 Massachusetts Institute Of Technology Thermodynamic adaptive phased array system for activating thermosensitive liposomes in targeted drug delivery
WO1999052505A1 (fr) * 1998-04-09 1999-10-21 Nycomed Imaging A.S. Utilisation d'agents de contraste particulaires dans l'imagerie diagnostique permettant d'etudier des parametres physiologiques
US6033645A (en) * 1996-06-19 2000-03-07 Unger; Evan C. Methods for diagnostic imaging by regulating the administration rate of a contrast agent

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5190766A (en) * 1990-04-16 1993-03-02 Ken Ishihara Method of controlling drug release by resonant sound wave
US5307812A (en) 1993-03-26 1994-05-03 General Electric Company Heat surgery system monitored by real-time magnetic resonance profiling
US5711300A (en) 1995-08-16 1998-01-27 General Electric Company Real time in vivo measurement of temperature changes with NMR imaging
US5720976A (en) * 1996-01-30 1998-02-24 Korea Advanced Institute Of Science And Technology Thermosensitive liposome and process for preparing the same
EP0800822A2 (fr) * 1996-04-11 1997-10-15 Mitsubishi Chemical Corporation Méthode de préparation de vésicules closes par réhydratation de vésicules déshydratées
US6033645A (en) * 1996-06-19 2000-03-07 Unger; Evan C. Methods for diagnostic imaging by regulating the administration rate of a contrast agent
EP0834309A2 (fr) * 1996-09-27 1998-04-08 Artur Herzog Dr. Mesmer Utilisation d'une solution de liposomes pour augmenter l'activité et/ou diminuer la toxicité de médicaments
US5810888A (en) * 1997-06-26 1998-09-22 Massachusetts Institute Of Technology Thermodynamic adaptive phased array system for activating thermosensitive liposomes in targeted drug delivery
WO1999052505A1 (fr) * 1998-04-09 1999-10-21 Nycomed Imaging A.S. Utilisation d'agents de contraste particulaires dans l'imagerie diagnostique permettant d'etudier des parametres physiologiques

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MORDON S ET AL: "FLUORESCENCE MEASUREMENT OF 805 NM LASER-INDUCED RELEASE OF 5,6-CF FROM DSPC LIPOSOMES FOR REAL-TIME MONITORING OF TEMPERATURE: AN IN VIVO STUDY IN RAT LIVER USING INDOCYANINE GREEN POTENTIATION", LASERS IN SURGERY AND MEDICINE,US,WILEY- LISS, NEW YORK, vol. 18, 1996, pages 265 - 270, XP000764458, ISSN: 0196-8092 *

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6671535B1 (en) 1999-11-09 2003-12-30 Biotex, Inc. Method and system for controlling heat delivery to a target
US6542767B1 (en) * 1999-11-09 2003-04-01 Biotex, Inc. Method and system for controlling heat delivery to a target
US9333038B2 (en) 2000-06-15 2016-05-10 Monteris Medical Corporation Hyperthermia treatment and probe therefore
US9387042B2 (en) 2000-06-15 2016-07-12 Monteris Medical Corporation Hyperthermia treatment and probe therefor
US10869721B2 (en) 2003-11-07 2020-12-22 Visualase, Inc. Cooled laser fiber and method for improved thermal therapy
US9339336B2 (en) 2003-11-07 2016-05-17 Visualase, Inc. Cooled laser fiber and method for improved thermal therapy
US10433909B2 (en) 2007-07-18 2019-10-08 Visualase, Inc. Systems and methods for thermal therapy
US9403029B2 (en) 2007-07-18 2016-08-02 Visualase, Inc. Systems and methods for thermal therapy
US11583338B2 (en) 2007-07-18 2023-02-21 Visualase, Inc. Systems and methods for thermal therapy
JP2012501707A (ja) * 2008-09-08 2012-01-26 アンスティテュ キュリィ 媒質をマーキングするための方法および装置、並びに、このような方法において使用可能なマーカー
WO2010026357A1 (fr) * 2008-09-08 2010-03-11 Institut Curie Procede et dispositif de marquage d'un milieu, et marqueur utilisable dans un tel procede.
FR2935604A1 (fr) * 2008-09-08 2010-03-12 Centre Nat Rech Scient Procede et dispositif de marquage d'un milieu, et marqueur utilisable dans un tel procede
US10188462B2 (en) 2009-08-13 2019-01-29 Monteris Medical Corporation Image-guided therapy of a tissue
US9211157B2 (en) 2009-08-13 2015-12-15 Monteris Medical Corporation Probe driver
US9271794B2 (en) 2009-08-13 2016-03-01 Monteris Medical Corporation Monitoring and noise masking of thermal therapy
US10610317B2 (en) 2009-08-13 2020-04-07 Monteris Medical Corporation Image-guided therapy of a tissue
US9510909B2 (en) 2009-08-13 2016-12-06 Monteris Medical Corporation Image-guide therapy of a tissue
US10548678B2 (en) 2012-06-27 2020-02-04 Monteris Medical Corporation Method and device for effecting thermal therapy of a tissue
US9486170B2 (en) 2014-03-18 2016-11-08 Monteris Medical Corporation Image-guided therapy of a tissue
US10342632B2 (en) 2014-03-18 2019-07-09 Monteris Medical Corporation Image-guided therapy of a tissue
US10092367B2 (en) 2014-03-18 2018-10-09 Monteris Medical Corporation Image-guided therapy of a tissue
US9700342B2 (en) 2014-03-18 2017-07-11 Monteris Medical Corporation Image-guided therapy of a tissue
US9504484B2 (en) 2014-03-18 2016-11-29 Monteris Medical Corporation Image-guided therapy of a tissue
US10675113B2 (en) 2014-03-18 2020-06-09 Monteris Medical Corporation Automated therapy of a three-dimensional tissue region
US9492121B2 (en) 2014-03-18 2016-11-15 Monteris Medical Corporation Image-guided therapy of a tissue
US9433383B2 (en) 2014-03-18 2016-09-06 Monteris Medical Corporation Image-guided therapy of a tissue
US10327830B2 (en) 2015-04-01 2019-06-25 Monteris Medical Corporation Cryotherapy, thermal therapy, temperature modulation therapy, and probe apparatus therefor
US11672583B2 (en) 2015-04-01 2023-06-13 Monteris Medical Corporation Cryotherapy, thermal therapy, temperature modulation therapy, and probe apparatus therefor
US11172821B2 (en) 2016-04-28 2021-11-16 Medtronic Navigation, Inc. Navigation and local thermometry

Also Published As

Publication number Publication date
AU2000255610A1 (en) 2002-01-08

Similar Documents

Publication Publication Date Title
Hijnen et al. Magnetic resonance guided high-intensity focused ultrasound for image-guided temperature-induced drug delivery
Heisterkamp et al. Interstitial laser coagulation for hepatic tumours
CA2562699C (fr) Systemes et procede servant a ameliorer l'ablation d'un tissu guidee par l'image
US7803103B2 (en) Methods and apparatus for intraocular brachytherapy
Rabkin et al. Biological and physical mechanisms of HIFU-induced hyperecho in ultrasound images
Willerding et al. Method of hyperthermia and tumor size influence effectiveness of doxorubicin release from thermosensitive liposomes in experimental tumors
AU2002303314B2 (en) Apparatus and method for delivering ablative laser energy and determining the volume of tumor mass destroyed
Blackwell et al. Proton resonance frequency shift thermometry: a review of modern clinical practices
AU2002303314A1 (en) Apparatus and method for delivering ablative laser energy and determining the volume of tumor mass destroyed
WO2002000298A1 (fr) Utilisation de liposomes thermosensibles
Eyrich et al. Temperature mapping of magnetic resonance‐guided laser interstitial thermal therapy (LITT) in lymphangiomas of the head and neck
Wong et al. Ultrasound ablation enhances drug accumulation and survival in mammary carcinoma models
Chen et al. MR-guided focused ultrasound: enhancement of intratumoral uptake of [3H]-docetaxel in vivo
Lu et al. Transcranial magnetic resonance-guided histotripsy for brain surgery: pre-clinical investigation
Mordon et al. Thermal damage assessment of blood vessels in a hamster skin flap model by fluorescence measurement of a liposome‐dye system
Usatoff et al. Update of Laser Induced Thermotherapy for Liver Tumours
Purdie et al. Dynamic contrast enhanced CT measurement of blood flow during interstitial laser photocoagulation: comparison with an Arrhenius damage model
Philipp et al. Color-coded duplex sonography as a new method for monitoring of laser-induced thermotherapy
Ritz et al. Laser-induced thermotherapy of liver metastases
Bär et al. Thermal threshold for localized Blood-Brain-Barrier disruption
AU2006203717B2 (en) Apparatus and method for delivering ablative laser energy and determining the volume of tumor mass destroyed
Castro et al. Near" real" time magnetic resonance images as a monitoring system for interstitial laser therapy: Experimental protocols
Choi Preoperative Image-guided Transcranial Histotripsy for Brain Cancer Treatment
WO2023235770A2 (fr) Matériaux et procédés de chauffage basé sur des nanoparticules magnétiques répétable pour ablation de tumeur
Philipp et al. Laser-induced thermotherapy of benign and malignant tumors controlled by color-coded duplex sonography

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP